Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
about
Interventions for central serous chorioretinopathy: a network meta-analysisAdvances in the treatment of central serous chorioretinopathyACUTE CENTRAL SEROUS CHORIORETINOPATHY: Factors Influencing Episode DurationPhotodynamic therapy rescue for subretinal fluid exacerbation after focal laser treatment in idiopathic central serous chorioretinopathy.One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.Topical nepafenac in treatment of acute central serous chorioretinopathy.The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.Diagnosis and interventions for central serous chorioretinopathy: review and update.The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.Central serous chorioretinopathy: update on pathophysiology and treatment.Focal laser photocoagulation and photodynamic therapy for lupus choroidopathy.Half-fluence photodynamic therapy to treat chronic central serous chorioretinopathy: A case series.The chorioretinal damage caused by different half parameters of photodynamic therapy in rabbits.System review and meta-analysis on photodynamic therapy in central serous chorioretinopathy.1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathyComparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.Photodynamic therapy and anti-vascular endothelial growth factor for acute central serous chorioretinopathy: a systematic review and meta-analysis.Subthreshold micropulse yellow laser treatment for nonresolving central serous chorioretinopathyPhotodynamic therapy: current role in the treatment of chorioretinal conditionsComparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathyLow-Fluence Photodynamic Therapy versus Subthreshold Micropulse Yellow Wavelength Laser in the Treatment of Chronic Central Serous Chorioretinopathy.Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic TherapyLong-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).Oral Mineralocorticoid-Receptor Antagonists: Real-Life Experience in Clinical Subtypes of Nonresolving Central Serous Chorioretinopathy With Chronic Epitheliopathy.Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy.Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.Characteristic findings of optical coherence tomography in retinal angiomatous proliferationSubfoveal choroidal thickness after photodynamic therapy in patients with acute idiopathic central serous chorioretinopathyRisk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy.Photodynamic therapy of symptomatic choroidal neviEvaluation of verteporfin pharmakokinetics--redefining the need of photosensitizers in ophthalmology.Central serous chorioretinopathy: a review of epidemiology and pathophysiology.Photodynamic therapy for central serous chorioretinopathy.Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: A 3-year follow-up study.Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy.Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.Subthreshold 577 nm micropulse laser treatment for central serous chorioretinopathy.Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report.Intravitreal bevacizumab for photodynamic therapy-induced massive macular detachment in acute central serous chorioretinopathy.
P2860
Q24186996-7E73AFF4-E0A6-498C-B485-247C6BC9496EQ28088443-2F410E7E-9FBD-4492-ABA6-81351DE0FE07Q30490648-7751B046-A472-4AA4-91C6-E0DAC8D146F5Q31003336-058BE5BB-8F8C-481C-BC32-B9DE02235631Q31112014-475FC6A3-22EC-4960-BE66-69DB9AB131EAQ33597082-81CF4237-1E13-466E-857F-F371B1E14B64Q33899231-0DAB4B96-6373-49F0-B185-1F85C61AF283Q33996055-A2EE44B5-1D27-440A-8049-B692DA251637Q34334335-C5FB38FE-5D49-45E3-AB86-9492B849EE0EQ34394791-E85F2C1D-8348-4B06-A077-41C1FDC316BBQ34587658-DBB08E20-DBD3-436A-BC12-4B7B0D34EEFCQ35087088-3021DDC8-EA53-48D2-9554-95CAF23BE27DQ35176611-D67DBB4F-7303-47B3-8209-8BEAD8D0F904Q35192101-A50B6542-CF23-46A3-8873-C02D4A9108FEQ35209632-246D0986-00C4-4E39-871E-6D37C6889EE1Q35677770-FF5AA88D-ADA9-4581-B1B1-F22921AD5F67Q35782233-0F3EB73C-6364-4693-8134-45B2D36AF226Q35826493-0FE19B17-1F91-4FC7-BD23-F0DC90B44C88Q35868001-4CAAB1C4-C019-4B95-A02D-DDEFFCB8EB01Q35888341-96D6F3DD-B96D-41F6-B002-609EA83B4A95Q36071607-5BB7F77E-7F81-4939-8D50-48E3E4609218Q36123646-E37279EE-ADF0-416F-B1BF-309AF56BC87FQ36135515-AC6C1186-18AF-4B46-A4B2-F2323701E6B7Q36407625-4AE6742C-E124-49CD-98C2-7E100808DFE1Q36663776-CB39170D-E179-42D5-9120-AFE8D16BD2ABQ36685428-9841DD21-7728-45D7-A68A-E71566AE2005Q36883236-C479E55D-C2B5-43FE-A14C-F41A571D0CD2Q37196177-53322A78-3945-4BB9-BFE3-9E935CE33C16Q37478532-CEA02249-B1E4-4BA4-B272-64D8FAEDF023Q37851307-03526E6F-1A9F-4A32-A6DE-8588A0FBF11BQ37973730-07E8B097-4B31-48EB-9638-3801BE8D029EQ38023892-AD81B3DB-494C-463C-BDCC-AB30D42FACB1Q38025702-800E387E-95C9-4DAD-8FD1-081198A1D1F9Q38221648-6FBA68CB-A653-4002-9548-453A7174C88EQ41106280-0E8782A9-3768-4F22-940E-6FAADD4AA3D7Q41190093-4C24768C-A983-4C15-8D2A-7840FABC8A11Q41362947-F5FE60F8-8311-4977-81CC-E79F347FCC71Q41544849-506BE279-C5F7-4606-86BE-A4E0C029825CQ41785680-62668145-274E-4BCE-9E9D-07E83F386E2DQ41959608-C477E6A0-CDFC-467F-80E5-B8905D305D59
P2860
Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Half-dose verteporfin photodyn ...... a randomized controlled trial.
@ast
Half-dose verteporfin photodyn ...... a randomized controlled trial.
@en
type
label
Half-dose verteporfin photodyn ...... a randomized controlled trial.
@ast
Half-dose verteporfin photodyn ...... a randomized controlled trial.
@en
prefLabel
Half-dose verteporfin photodyn ...... a randomized controlled trial.
@ast
Half-dose verteporfin photodyn ...... a randomized controlled trial.
@en
P2093
P1433
P1476
Half-dose verteporfin photodyn ...... a randomized controlled trial.
@en
P2093
David T L Liu
Ricky Y K Lai
Timothy Y Y Lai
Wai-Man Chan
P304
P356
10.1016/J.OPHTHA.2008.04.014
P577
2008-06-05T00:00:00Z